Treatment of Rheumatoid arthritis in Ayurveda
Phase 3
- Conditions
- Health Condition 1: M059- Rheumatoid arthritis with rheumatoid factor, unspecified
- Registration Number
- CTRI/2024/08/072452
- Lead Sponsor
- Post Graduate Institute Of Ayurveda Studies and Research Jodhpur
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1.The Patients between the age group of 20 to 70 years in both sexes presenting with clinical features of Amavata.
2.Pre-diagnosed or patient having symptoms of Amavata as mentioned in classical ayurvedic texts.
3.Clinically diagnosed and confirm patients on Amavata.
4.Patients willing to sign the consent form.
Exclusion Criteria
1.Patients of uncontrolled diabetes mellitus, severe anemia, malignancy.
2.Patients having any other severe disease.
3.Pregnant women and lactating mother.
4.Patient below age of 20 & above 70.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Changes in subjective parameterTimepoint: 45 days
- Secondary Outcome Measures
Name Time Method Changes in Objective ParametersTimepoint: 45 days
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
How do Pippali Paka and Saptamushtika Yusha modulate cytokine pathways (e.g., TNF-alpha, IL-6) in rheumatoid arthritis with rheumatoid factor (M059)?
What is the comparative efficacy and safety of Pippali Paka/Saptamushtika Yusha versus conventional DMARDs like methotrexate in treating M059 rheumatoid arthritis?
Which biomarkers (e.g., ACPA, CRP, RF levels) predict response to Pippali Paka and Saptamushtika Yusha in Amavata-associated rheumatoid arthritis (M059)?
What are the adverse event profiles and management strategies for Pippali Paka/Saptamushtika Yusha in Phase III trials for rheumatoid arthritis?
Are there synergistic effects when combining Pippali Paka/Saptamushtika Yusha with biologic DMARDs (e.g., TNF inhibitors) in rheumatoid arthritis treatment?